CJC-1295 vs Sermorelin
Two GHRH-based growth-hormone secretagogues compared honestly — what raising GH actually proves, the different regulatory histories, and why the popular anti-aging claims stay unsupported.
Both are GHRH analogs that act on the same pituitary receptor, and both raise or stimulate growth hormone — a biomarker effect, not a proven clinical outcome. The popular adult "anti-aging" and body-composition claims are unsupported for both. Sermorelin has the better-validated biomarker effect and a genuine (historical, pediatric) approval behind it, while CJC-1295 is a never-approved research chemical. But for the uses people actually buy them for, both are unproven in humans — and neither is an approved therapeutic today.
| CJC-1295 | Sermorelin | |
|---|---|---|
| Mechanism | Long-acting GHRH analog — binds the GHRH receptor on pituitary somatotrophs | GHRH (1-29) analog — binds the same GHRH receptor |
| Regulatory status | Research chemical — never FDA-approved for any use | Withdrawn — formerly FDA-approved (Geref, 1997); now available only via compounding pharmacies |
| Best evidence | Grade C — raises GH and IGF-1 in one small human study (Teichman 2006) | Grade B — reliably stimulates GH release; the basis of its former approval |
| Human trial evidence | A single phase-1/2 pharmacokinetic study; no clinical-outcome trials | Validated for pediatric GH-deficiency treatment and GHRH stimulation testing; no adult-wellness outcome trials |
| Adult body-composition / anti-aging | Grade U–E — heavily marketed, no controlled human outcome data | Grade U — the dominant modern marketing claim, without controlled trials |
| Half-life / dosing | With DAC ~6–8 days; without DAC (Modified GRF 1-29) ~30 minutes | Very short — roughly 10–20 minutes |
| Common side effects / safety | Injection-site reactions, flushing, headache; long-term safety unknown | Injection-site reactions, flushing, headache, nausea; long-term adult safety unknown |
| WADA status | Prohibited at all times (S2) | Prohibited at all times (S2) |
How to read this comparison
CJC-1295 and sermorelin work the same way: both are analogs of growth-hormone-releasing hormone (GHRH) that bind the pituitary GHRH receptor and prompt the gland to release its own growth hormone. The single most important thing to understand about both is that raising GH and IGF-1 is a biomarker effect, not a clinical outcome. These are research chemicals (sermorelin, in compounded form, is not an FDA-approved finished drug), and “makes a hormone level go up” is a long way from “burns fat,” “builds muscle,” or “slows aging.”
On the biomarker itself, sermorelin has the stronger record. Its ability to stimulate GH release is Grade B and is exactly what earned its original FDA approval in 1997 (as Geref) for pediatric GH-deficiency testing and treatment. CJC-1295’s evidence that it raises GH and IGF-1 is Grade C — real, but resting on a single small pharmacokinetic study in healthy adults.
On the claims people actually buy them for — adult “anti-aging,” body composition, sleep, vitality — neither has controlled human outcome evidence. For sermorelin that is Grade U; for CJC-1295 those claims run from U to E (unsupported). The historical sermorelin evidence came from a supervised pediatric setting, not open-ended adult wellness use, so it does not transfer to the way the compound is marketed today.
The regulatory histories differ in a way worth being precise about. Sermorelin was approved; the branded product was discontinued in 2008 for commercial reasons, and the FDA specifically determined it was not pulled for safety or effectiveness. All sermorelin dispensed now is compounded and not FDA-approved as a finished drug. CJC-1295 was never approved for anything and is sold purely as a research chemical — with the added confusion that “with DAC” (multi-day) and “without DAC” (Modified GRF 1-29, ~30 minutes) are pharmacologically different molecules sold under one name.
Both are prohibited in sport under WADA’s S2 category. Both carry the same open question — whether chronically stimulating GH in healthy adults does anything worthwhile, and whether it is safe long-term — and for both, the honest answer is that no controlled trial has shown it. This page summarizes the research and regulatory record; it is not medical advice or an endorsement of use.
A note on "dose"
Any doses shown here are the amounts studied in trialsor the approved label schedule — not a recommendation, and not the same thing as a dose someone reports using online. See how we separate dose language.
References
- Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006
- Federal Register. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn for Reasons of Safety or Effectiveness (2013)